Real-world data (RWD) are defined as information collected about patients as a routine part of treatment. To understand the status of RWD initiatives in oncology in the UK, an online survey and in-person workshop were conducted which aimed to characterise current perceptions of RWD, establish where real-world evidence (RWE) could support unmet clinical need, and to identify the barriers and solutions to obtaining this evidence. Self-selecting health care professionals including oncologists, physicists, radiographers, and health data researchers, as well as patient representatives, participated in an anonymous survey (N = 55) and/or a 1-day workshop (N = 46). The workshop consisted of introductory presentations followed by three 1 hour grouped breakout sessions. An inductive thematic analysis synthesizing the outcomes of the survey and workshop was carried out post hoc. Despite issues of perceived poor data quality and the prevalence of unstructured data, 92% of survey respondents recognised the potential of RWD to provide novel evidence. Suggested applications of RWE were validation of trial results in the general population, continuous evaluation of new technologies, decision-making in rare disease groups, and resource allocation. Barriers to progression of RWD initiatives identified were data accessibility, data quality, and prioritisation. Potential solutions include streamlining information governance processes, training staff in data science skills, and demonstrating clinical benefit. The potential of RWD to provide novel evidence is strongly recognised in the UK radiotherapy community. While barriers to progress were identified, none of them are insurmountable. To move forwards, the profile of RWE needs to be elevated to attract higher prioritisation and resourcing.
Objective. This study aimed to optimise Cone Beam Computed Tomography (CBCT) protocols for head and neck (H&N) radiotherapy treatments using a 3D printed anthropomorphic phantom. It focused on precise patient positioning in conventional treatment and adaptive radiotherapy (ART). Approach. Ten CBCT protocols were evaluated with the 3D-printed H&N anthropomorphic phantom, including one baseline protocol currently used at our centre and nine new protocols. Adjustments were made to milliamperage and exposure time to explore their impact on radiation dose and image quality. Additionally, the effect on image quality of varying the scatter correction parameter for each of the protocols was assessed. Each protocol was compared against a reference CT scan. Usability was assessed by three Clinical Scientists using a Likert scale, and statistical validation was performed on the findings. Main results. The work revealed variability in the effectiveness of protocols. Protocols optimised for lower radiation exposure maintained sufficient image quality for patient setup in a conventional radiotherapy pathway, suggesting the potential for reducing patient radiation dose by over 50% without compromising efficacy. Optimising ART protocols involves balancing accuracy across brain, bone, and soft tissue, as no single protocol or scatter correction parameter achieves optimal results for all simultaneously. Significance. This study underscores the importance of optimising CBCT protocols in H&N radiotherapy. Our findings highlight the potential to maintain the usability of CBCT for bony registration in patient setup while significantly reducing the radiation dose, emphasizing the significance of optimising imaging protocols for the task in hand (registering to soft tissue or bone) and aligning with the as low as reasonably achievable principle. More studies are needed to assess these protocols for ART, including CBCT dose measurements and CT comparisons. Furthermore, the novel 3D printed anthropomorphic phantom demonstrated to be a useful tool when optimising CBCT protocols.
Background/Objectives: Symptomatic breast services face increasing diagnostic demand, while younger women with benign-appearing ultrasound lesions frequently undergo biopsy despite a low prevalence of malignancy. This study evaluated whether a rule-based clinical decision algorithm combining patient age, clinician ultrasound assessment and artificial intelligence (AI) decision support could identify a subgroup in whom biopsy might be avoided without excluding malignancy from the biopsy pathway. Methods: A retrospective analysis was performed using prospectively collected service-evaluation data from 240 patients (254 lesions) attending a large NHS breast unit between May and December 2025. Clinician ultrasound assessment, KOIOS DS Breast AI output and histopathology were recorded. Lesions in women aged ≤ 35 years were eligible for biopsy avoidance when clinician assessment was U2 or U3 and the KOIOS AI assessment was BI-RADS 2. Histopathology was the reference standard. Secondary analyses compared clinician and AI diagnostic performance. An illustrative five-year budget impact analysis was undertaken from the NHS provider perspective. Results: Among 151 lesions in women aged ≤ 35 years, 146 were benign and five were malignant. The algorithm would have classified 87 lesions for biopsy avoidance (57.6%; 95% CI, 49.3–65.6%). Of these, 67 (77.0%) had a clinician U3 classification. All 87 were benign on histopathology (100%; 95% CI, 95.8–100%), while all five malignant lesions remained in the biopsy pathway. Clinician assessment showed higher specificity than AI (99.1% vs. 75.7%), whereas AI showed higher sensitivity (96.9% vs. 81.3%). Avoidance of 87 biopsies was associated with approximately £85,000 in gross cost offsets during the evaluation period in the illustrative economic model. Conclusions: The AI-supported clinical decision algorithm could substantially reduce benign biopsy activity in younger women while maintaining cancer detection in this cohort. The small number of malignancies, single-centre design and biopsy population mean that prospective multicentre validation is required before routine clinical implementation.